CCR5拮抗剂初治患者中HIV-1对CCR5拮抗剂的原发性基因型耐药性。
Primary genotypic resistance of HIV-1 to CCR5 antagonists in CCR5 antagonist treatment-naive patients.
作者信息
Soulié Cathia, Malet Isabelle, Lambert-Niclot Sidonie, Tubiana Roland, Thévenin Monique, Simon Anne, Murphy Robert, Katlama Christine, Calvez Vincent, Marcelin Anne-Geneviève
机构信息
UMPC Université Paris 06, Paris, France.
出版信息
AIDS. 2008 Oct 18;22(16):2212-4. doi: 10.1097/QAD.0b013e328313bf9c.
Resistance to CCR5 antagonists can be driven by mutations in gp120. Sequences from 323 anti-CCR5 naive patients were analyzed for the presence of previously described in-vivo or in-vitro resistance mutations to CCR5 antagonists located in the V3 loop of gp120. The V3 loop region was rather polymorphic, and 7.3% of patients showed viruses with combinations of mutations in V3 loop previously described to be involved in maraviroc resistance, a licensed CCR5 antagonist.
对CCR5拮抗剂的耐药性可能由gp120中的突变引起。分析了323例初治抗CCR5患者的序列，以确定位于gp120 V3环中先前描述的对CCR5拮抗剂的体内或体外耐药性突变的存在情况。V3环区域多态性较高，7.3%的患者体内病毒具有V3环中先前描述的与马拉维若（一种已获许可的CCR5拮抗剂）耐药性相关的突变组合。
Zotero 插件